S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:OPT

Opthea (OPT) Stock Price, News & Analysis

$3.30
-0.10 (-2.94%)
(As of 04/19/2024 ET)
Today's Range
$3.20
$3.41
50-Day Range
$2.88
$4.14
52-Week Range
$1.60
$4.42
Volume
3,723 shs
Average Volume
13,084 shs
Market Capitalization
$192.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Opthea MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
324.2% Upside
$14.00 Price Target
Short Interest
Healthy
0.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.57) to ($2.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

584th out of 911 stocks

Biological Products, Except Diagnostic Industry

96th out of 151 stocks

OPT stock logo

About Opthea Stock (NASDAQ:OPT)

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

OPT Stock Price History

OPT Stock News Headlines

Chances are you know the firms on this list
These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…
Opthea Appoints Sujal Shah to the Board of Directors
Chances are you know the firms on this list
These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…
Opthea Limited (OPT)
Opthea Limited ADRs Rise 31% on Raised Funding
Opthea to Present at the FLORetina 2023 Congress
See More Headlines
Receive OPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/20/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OPT
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$16.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+324.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$110,000.00
Book Value
($0.10) per share

Miscellaneous

Free Float
56,526,000
Market Cap
$192.72 million
Optionable
Not Optionable
Beta
1.19
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Megan Baldwin M.A.I.C.D. (Age 49)
    MAICD, Ph.D., Founder, Chief Innovation Officer & Executive Director
    Comp: $599.73k
  • Ms. Judith J. Robertson B.A. (Age 63)
    M.B.A., Chief Commercial Officer
    Comp: $588.59k
  • Ms. Karen Adams CPA (Age 52)
    VP of Finance & Company Secretary
    Comp: $305.14k
  • Dr. Frederic Guerard M.S. (Age 51)
    Pharm.D., Chief Executive Officer
  • Mr. Peter F. Lang M.B.A. (Age 51)
    Chief Financial Officer
  • Ms. Sarika Gulhar Ph.D.
    Executive Director of Human Resources
  • Dr. Michael Gerometta Ph.D. (Age 59)
    Head of Chemistry, Manufacturing & Controls Development
    Comp: $127.66k
  • Mr. Bruno Gagnon BPHARM (Age 55)
    M.Sc., Senior Vice President of Global Clinical Operations
  • Dr. Kenneth Sall
    Chief Medical Officer
  • Dr. Fang Li Ph.D.
    Senior Vice President of Regulatory Affairs

OPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Opthea stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opthea in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPT shares.
View OPT analyst ratings
or view top-rated stocks.

What is Opthea's stock price target for 2024?

2 analysts have issued 1 year target prices for Opthea's stock. Their OPT share price targets range from $12.00 to $16.00. On average, they anticipate the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 324.2% from the stock's current price.
View analysts price targets for OPT
or view top-rated stocks among Wall Street analysts.

How have OPT shares performed in 2024?

Opthea's stock was trading at $2.95 at the start of the year. Since then, OPT shares have increased by 11.9% and is now trading at $3.30.
View the best growth stocks for 2024 here
.

What guidance has Opthea issued on next quarter's earnings?

Opthea updated its FY 2023 earnings guidance on Tuesday, January, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $47.5 million-$47.5 million.

When did Opthea IPO?

Opthea (OPT) raised $161 million in an IPO on Friday, October 16th 2020. The company issued 9,300,000 shares at $17.26 per share. Citigroup and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

How do I buy shares of Opthea?

Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners